期刊文献+

The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future 被引量:2

原文传递
导出
摘要 Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally.Hepatocellular carcinoma(HCC)represents nearly 90%of primary liver cancers,and constitutes a major health problem worldwide(1).When diagnosed at an early stage of the disease,HCC may benefit from potentially curative treatments such as liver resection,liver transplantation or local ablation.Despite effectiveness of treatment in early and very early stages,most patients are diagnosed or progress to an intermediate or advanced stage,in which treatment options are limited and the prognosis is poor(2).
出处 《Hepatobiliary Surgery and Nutrition》 SCIE 2018年第6期487-489,共3页 肝胆外科与营养(英文)
  • 相关文献

参考文献1

共引文献538

同被引文献13

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部